Shattuck Labs

#Immuno-Oncology #Cancer Immunotherapy #Tumor Microenvironment #Inflammatory Disease #Cytokine Receptor Modulation

Shattuck Labs is a clinical-stage biotechnology company developing novel biotherapeutics based on its proprietary Agonist Redirected Checkpoint (ARC) platform, which combines elements of antibody and cytokine receptor signaling in single fusion proteins for the treatment of cancer and inflammatory disease.

Company Info

Sector: Biotechnology / Immuno-Oncology

Headquarters: Austin, Texas, USA

Founded: 2016

Website: www.shattucklabs.com/

Upcoming Milestones & Key Dates

H2 2026

Clinical Trial

Phase 1 dose-expansion data for SL-172154 in solid tumors

Q4 2026

Clinical Trial

SL-115154 Phase 1 initial safety/efficacy update

Clinical Development Pipeline

SL-172154 (now SL-279252)

Target: PD-1xOX40L ARC fusion protein

Advanced solid tumors (PD-1/PD-L1 relapsed/refractory) and cutaneous squamous cell carcinoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SL-115154

Target: PD-1x4-1BBL ARC fusion protein

PD-1/PD-L1 insensitive solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SL-279252

Target: PD-1xOX40L ARC fusion protein

Inflammatory disease (undisclosed)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Shattuck Raises $75M; Servier Inks Neuro ASO Pact with n-Lorem Foundation ↗

Shattuck Labs closed a $75M financing round, while Servier announced a partnership with the n-Lorem Foundation to develop antisense oligonucleotide (ASO) therapies for ultra-rare neurological diseases.

Leadership Team

Dr. Taylor Schreiber

Founder, Chief Executive Officer and Chief Scientific Officer

Dr. Lini Pandite

Chief Medical Officer

Andrew R. Neill

Chief Financial Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →